Safety of the Use of Radioactive Iodine in Patients with Hyperthyroidism

TY - JOUR

T1 - Safety of the Use of Radioactive Iodine in Patients with Hyperthyroidism

AU - Peacock, Justin G.

AU - Clemenshaw, Michael N.

AU - Banks, Kevin P.

N1 - Funding Information: Author Affiliations: Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Kitahara, Berrington de González); Hirosoft International, Eureka, California (Preston). Corresponding Author: Cari M. Kitahara, PhD, MHS, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Rm 7E-536, Bethesda, MD 20892 ([email protected]). Conflict of Interest Disclosures: None reported. Funding Information: Author Affiliations: Department of Neurology, University of Michigan, Ann Arbor (Burke); Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan (Burke, Langa); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor (Burke, Langa); Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor (Langa); Institute for Social Research, University of Michigan, Ann Arbor (Langa); Institute of Gerontology, University of Michigan, Ann Arbor (Langa). Corresponding Author: James F. Burke, MD, MS, Department of Neurology, University of Michigan, 2800 Plymouth Rd, Bldg 14, Room G105, Ann Arbor, MI 48109 ([email protected]). Conflict of Interest Disclosures: Dr Langa reports receiving grants from the National Institute on Aging of the National Institutes of Health and from the Alzheimer’s Association. No other disclosures were reported. 1. Langa KM, Burke JF. Preclinical Alzheimer disease: early diagnosis or overdiagnosis? JAMA Intern Med. 2019;179(9):1161-1162. doi:10.1001/ jamainternmed.2019.2629 2. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000 3. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. doi:10.1002/14651858.CD005593

PY - 2019/12

Y1 - 2019/12

UR - https://www.scopus.com/pages/publications/85075778648

UR - https://www.scopus.com/pages/publications/85075778648#tab=citedBy

U2 - 10.1001/jamainternmed.2019.5117

DO - 10.1001/jamainternmed.2019.5117

M3 - Letter

C2 - 31790527

AN - SCOPUS:85075778648

SN - 2168-6106

VL - 179

SP - 1737

EP - 1738

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 12

ER -